Urinary excretion of phenobarbitone and its metabolites in chronically treated patients.
The elimination of phenobarbitone (PB) was studied in 14 chronically treated epileptic patients under steady state conditions. PB, [S]-PB-N-glucoside ([S]-PB-N-G) and p-hydroxy-PB (p-OH-PB) were assayed in urine by a HPLC method. Some 57% of the daily dose was recovered in urine, 14% as [S]-PB-N-G, 16% as p-OH-PB (conjugated plus non-conjugated) and 27% as unaltered PB. Thus PB-N-G formation contributed significantly to the elimination of PB during long-term administration of the drug, and there was reason to suspect that some of the PB-N-G formed may have already been degraded to untraced products before excretion from the body.
Department of Medicine, University of Queensland, Royal Brisbane Hospital, Australia.
I
I
Bernus
R G
RG
Dickinson
W D
WD
Hooper
M J
MJ
Eadie
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001711:Biotransformation; D002851:Chromatography, High Pressure Liquid; D004827:Epilepsy / Q000188:drug therapy / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000652:urine*
C043855:phenobarbital-N-glucoside; D010634:Phenobarbital